tiprankstipranks
Trending News
More News >
Natural Alternatives International (NAII)
NASDAQ:NAII

Natural Alternatives International (NAII) AI Stock Analysis

Compare
85 Followers

Top Page

NAII

Natural Alternatives International

(NASDAQ:NAII)

Select Model
Select Model
Select Model
Neutral 46 (OpenAI - 5.2)
Rating:46Neutral
Price Target:
$2.50
▼(-20.63% Downside)
Action:ReiteratedDate:02/15/26
The score is held down primarily by weak profitability (operating and net losses with low gross margin) and increased leverage, despite a strong TTM revenue rebound. Technical signals also remain soft (negative MACD, sub-50 RSI, and price below short-term moving averages). Positive operating and free cash flow provide some support, but losses and volatility keep the overall profile pressured.
Positive Factors
Diversified business model
NAII operates both a contract manufacturing business and branded-product lines while commercializing proprietary patented/trademarked ingredients. This mix supports multiple revenue channels, reduces single-customer risk, and creates cross-sell and margin diversification over the medium term.
Strong revenue rebound
A 54.9% TTM revenue rebound signals recovering demand or successful customer wins. Sustained top-line growth improves scale economics potential, supports capacity utilization in manufacturing, and provides a base to restore margins and reinvest in branded growth over the next several quarters.
Positive cash generation
Despite accounting losses, NAII generates positive operating cash flow and FCF, showing the core business can produce liquidity. Persistent cash generation supports working capital needs, funds organic investment, and reduces near-term refinancing pressure versus pure accrual profit metrics.
Negative Factors
Low margins and losses
Very low gross margins and a sizable net loss indicate structural profitability weakness. Persistent margin compression limits internal reinvestment, impairs ability to scale branded initiatives profitably, and raises dependence on volume increases to drive meaningful earnings recovery.
Rising leverage and covenant risk
Material debt increase and a covenant waiver signal reduced financial flexibility. Higher leverage heightens refinancing and interest-rate sensitivity, constraining strategic choices and increasing the risk that future operational setbacks could trigger further lender action or costly covenant renegotiations.
Earnings & cash flow volatility
The company has swung from multi-year profits to recent losses while free cash flow declined sharply. This volatility complicates forecasting, budgeting, and capital allocation, and reduces investor confidence in management's ability to sustainably translate revenue growth into stable profits.

Natural Alternatives International (NAII) vs. SPDR S&P 500 ETF (SPY)

Natural Alternatives International Business Overview & Revenue Model

Company DescriptionNatural Alternatives International, Inc. engages in formulating, manufacturing, and marketing nutritional supplements in the United States, Europe, Asia, and internationally. The company operates in two segments, Private-Label Contract Manufacturing, and Patent and Trademark Licensing. It offers private-label contract manufacturing services to companies that market and distribute vitamins, minerals, herbal, and other nutritional supplements, as well as other health care products. The company also provides strategic partnering services, such as customized product formulation, clinical studies, manufacturing, marketing support, international regulatory and label law compliance, international product registration, packaging in multiple formats and labeling design, scientific research, proprietary ingredients, customer-specific nutritional product formulation, product testing and evaluation, packaging and delivery system design, and regulatory review. In addition, it sells beta-alanine ingredient under the CarnoSyn and SR CarnoSyn names. The company manufactures products in various forms, including capsules, tablets, chewable wafers, and powders. Its private-label contract manufacturing customers include companies that market nutritional supplements through direct sales marketing channels, direct to consumer e-commerce channels, and retail stores. Natural Alternatives International, Inc. was founded in 1980 and is headquartered in Carlsbad, California.
How the Company Makes MoneyNAII generates revenue primarily from two sources. (1) Contract Manufacturing: NAII earns money by providing manufacturing services to other companies (brands and marketers of nutritional supplements). Revenue in this segment typically comes from fees embedded in the sale of finished goods produced for customers—i.e., NAII manufactures and sells completed supplement products (such as capsules, tablets, powders, and related formats) to clients that then sell under their own brands. This stream is driven by production volumes, long-term customer relationships, and NAII’s manufacturing capabilities (including quality systems and regulatory compliance). (2) Branded Products: NAII also earns revenue from selling its own branded nutritional supplement products to consumers and/or retailers/distributors. In this model, revenue is generated from product sales under NAII-owned brands, with earnings influenced by brand demand, marketing, distribution reach, and pricing. In addition, NAII monetizes proprietary supplement ingredients and intellectual property by supplying those ingredients for use in products (either within contract-manufactured items or in broader ingredient sales) and supporting their commercialization through trademarks and patents. Specific details on material partnerships, customer concentration, or the relative contribution of each stream are null.

Natural Alternatives International Key Performance Indicators (KPIs)

Any
Any
Revenue by Segment
Revenue by Segment
Shows how much each business segment contributes to overall sales, indicating which areas drive growth and where diversification or expansion opportunities may exist.
Chart InsightsNatural Alternatives International's Private Label Contract Manufacturing segment is showing signs of recovery after a dip in 2023, with a steady upward trend into 2025. This suggests a potential stabilization and renewed demand. Meanwhile, the Patent and Trademark Licensing segment remains volatile, with recent declines indicating potential challenges in monetizing intellectual property. Investors should watch for strategic shifts or new partnerships that could stabilize licensing revenues and capitalize on manufacturing momentum.
Data provided by:The Fly

Natural Alternatives International Financial Statement Overview

Summary
Revenue rebounded sharply (+54.9% TTM), but profitability has deteriorated materially with low gross margin (~8.1%) and a significant net loss (~-14.4% net margin). Leverage has increased meaningfully (debt ~0.86x equity) after covenant issues, reducing flexibility. Positive operating cash flow (~$6.4M) and positive free cash flow (~$1.7M) are supportive, but FCF fell sharply versus the most recent annual period and earnings stability remains weak.
Income Statement
22
Negative
TTM (Trailing-Twelve-Months) results show a sharp revenue rebound (+54.9%), but profitability has deteriorated materially: gross margin is low (~8.1%) and the company is operating at a loss (negative operating margin and negative net margin of ~-14.4%), with a sizable net loss. Over the last several annual periods, the business swung from solid profits (2021–2022) to a small profit (2023) and then to significant losses (2024 and 2025), signaling weak earnings stability and likely cost/price or mix pressure despite improving sales.
Balance Sheet
45
Neutral
Leverage has increased meaningfully versus earlier years: total debt rose to about $106.5M in TTM (Trailing-Twelve-Months) from roughly $59–60M in the last two annual reports, while equity is about $67.0M. Debt sits at ~0.86x equity, which is notably higher than 2021–2023 levels and reduces financial flexibility. With losses, return on equity is strongly negative in TTM (Trailing-Twelve-Months), though the company still has a meaningful equity base relative to total assets.
Cash Flow
52
Neutral
Cash generation is a relative bright spot: TTM (Trailing-Twelve-Months) operating cash flow is positive (~$6.4M) and free cash flow is also positive (~$1.7M), showing the business can generate cash even while reporting accounting losses. However, free cash flow fell sharply versus the most recent annual period (large negative growth), and cash flow coverage versus earnings is only moderate, indicating cash performance may be volatile and not yet consistently strong.
BreakdownTTMJun 2024Jun 2023Jun 2022Jun 2021Jun 2020
Income Statement
Total Revenue134.47M129.86M113.80M154.01M170.97M178.52M
Gross Profit11.56M9.29M6.87M18.16M30.51M30.44M
EBITDA-364.00K-2.70M-4.46M11.09M20.66M16.58M
Net Income-12.25M-13.57M-7.22M2.52M10.71M10.77M
Balance Sheet
Total Assets153.30M151.94M162.34M134.15M146.00M120.28M
Cash, Cash Equivalents and Short-Term Investments3.75M12.32M11.98M13.60M21.83M32.13M
Total Debt106.51M59.03M60.29M30.93M31.84M16.48M
Total Liabilities86.25M83.51M79.75M45.38M57.48M40.20M
Stockholders Equity67.05M68.43M82.59M88.77M88.52M80.08M
Cash Flow
Free Cash Flow-5.24M2.32M-4.51M-6.50M-14.62M15.70M
Operating Cash Flow-1.01M5.93M-1.50M7.02M11.87M20.81M
Investing Cash Flow-4.22M-3.61M-3.02M-13.47M-26.46M-5.04M
Financing Cash Flow326.00K-1.97M2.89M-1.78M4.29M-14.11M

Natural Alternatives International Technical Analysis

Technical Analysis Sentiment
Negative
Last Price3.15
Price Trends
50DMA
3.52
Negative
100DMA
3.31
Negative
200DMA
3.34
Negative
Market Momentum
MACD
-0.20
Negative
RSI
37.60
Neutral
STOCH
40.43
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NAII, the sentiment is Negative. The current price of 3.15 is above the 20-day moving average (MA) of 2.78, below the 50-day MA of 3.52, and below the 200-day MA of 3.34, indicating a bearish trend. The MACD of -0.20 indicates Negative momentum. The RSI at 37.60 is Neutral, neither overbought nor oversold. The STOCH value of 40.43 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NAII.

Natural Alternatives International Risk Analysis

Natural Alternatives International disclosed 22 risk factors in its most recent earnings report. Natural Alternatives International reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Natural Alternatives International Peers Comparison

Overall Rating
UnderperformOutperform
Sector (62)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
62
Neutral
$20.33B14.63-3.31%3.23%1.93%-12.26%
61
Neutral
$428.76M22.9912.18%6.62%-7.85%
56
Neutral
$316.99M33.563.20%5.88%-68.62%
56
Neutral
$66.40M70.5424.97%2.81%16.77%143.30%
55
Neutral
$129.69M50.7017.12%12.44%-20.33%
46
Neutral
$16.68M-2.11-17.43%18.19%-35.22%
45
Neutral
$60.47M-0.21-111.73%-10.13%-532.32%
* Consumer Defensive Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
NAII
Natural Alternatives International
2.70
-0.80
-22.86%
NATR
Nature's Sunshine Products
24.49
11.48
88.24%
HAIN
Hain Celestial
0.66
-3.15
-82.60%
USNA
USANA Health
17.34
-11.80
-40.49%
LFVN
LifeVantage
5.19
-11.44
-68.80%
FTLF
FitLife Brands
13.81
-0.14
-1.00%

Natural Alternatives International Corporate Events

Private Placements and FinancingRegulatory Filings and Compliance
Natural Alternatives Resolves Credit Agreement Issues
Positive
Dec 17, 2025

Natural Alternatives International, Inc. announced that it failed to comply with certain financial covenants under its Credit Agreement with Wells Fargo Bank for its fiscal first quarter ending September 30, 2025. To address the issue, the company successfully negotiated a Waiver and Release Agreement with Wells Fargo on December 17, 2025, ensuring that all defaults were waived and the Credit Agreement remains fully operational. This resolution reinforces the company’s ability to maintain its financial arrangements and supports its ongoing operations, bringing stability for stakeholders moving forward.

The most recent analyst rating on (NAII) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on Natural Alternatives International stock, see the NAII Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Feb 15, 2026